Under the expert supervision of Dr. Richard Pitch, neuroCare Centers of America is pleased to open its second center in Melville, Long Island, NY
Bei den "Internationalen Nachrichten" handelt es sich um alle Nachrichten, die auf englisch verfasst und veröffentlicht wurden. Hier sind Nachrichten aller neuroCare Geschäftsbereich zu finden.
neuroCare’s brand of evidence-based and sustainable therapies for ADHD, Depression & OCD, will soon be available in Melbourne as the company joins with the Listen And Learn Centre.
This year neuroCare was the proud sponsor of the ADHD Heroes team, entered by ‘ADDults with ADHD,’ a charity dedicated to improving the lives of adults and families dealing with ADHD.
The Dutch Health Authority advises health insurance companies to reimburse the therapy for treatment resistant depression
Leading expert on personalised rTMS, Dr. Martijn Arns visits Asia-Pacific for 2-Day practitioner workshops
Dr. Ross Walker from Australia's talk-back radio program, Healthy Living, talks to neuroCare's Dr. Mark Ryan about rTMS and depression and the importance of sleep.
A research team in Germany publishes strongest level of evidence for SCP neurofeedback as a valid intervention of ADHD.
Study at Brainclinics Research Institute suggests addressing sleep in OCD patients may improve response to rTMS
Research Institute Brainclinics will present new data validating proof-of-concept behind the Neuro-Cardiac Guided TMS at this year's Brain Stimulation Conference in Barcelona.
According to the World Health Organisation (WHO) more than 4% of the global population live with depression.
Earlier this month Dr. Kerstin Mayer presented courses on Neurofeedback and tDCS together with Dr. Reza Rostami from the University of Tehran and Atiyeh Clinic.
In an article recently published in Psychiatric Annals (Vol 46), Dr. Kerstin Mayer and Dr. Martijn Arns review the evidence for the efficacy of neurofeedback in psychiatric disorders.
The 10th of October marked "World Mental Health Day", also a part of "Mental Health Week" in Australia. The day encourages the public to speak opeanly about mental health education, awareness and advocacy against social stigma. Hashhtags like #light-up-purple and #worldmentalhealthday having been trending on Facebook and Twitter as messages of support and awareness are shared all over the world.
In the latest issue of the journal EMBO Molecular Medicine, esteemed psychologists from the University of Bochum in Germany claim the effects of psychiatric drugs used for treating mental illnesses such as depression, anxiety and ADHD only have short-term effects with negative long-term repercussions.
Experts from the cognitive neuroscience research community have penned an open letter expressing their concern about members of the public applying electric current to the brain with home-use tDCS devices.
Economists put a dollar figure on the cost of mental health annually in Australia, estimating the financial impact is equivalent to 12% of annual economic output, mostly due to increased days of work due to poor health and performance.
From June 1, 2016, U.S. based rTMS clinical use pioneer Stanford W. Miller will lead the neuroCare Group’s expansion into North America as Managing Director.
The first clinical study on the effect of neurofeedback in adult patients with ADHD has been successfully carried out at the University of Tübingen.
Authors Christopher Davey and Andrew Chanen call for alternatives to anti-depressant medication to improve outcomes for patients suffering depression. They highlight in their article that while anti-depressants still have an important role in patient treatment, medication is more effective if given in combination with other therapies. You can read the full article here.
Workplace Editor Anna Patty of the Sydney Morning Herald explains how psychiatrists in Australia are increasingly becoming dissatisfied and find it hard to do their work with the limited resources available in hospitals and the community. The full article can be found here.